Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386222 | 0.88 | KMT2A (0.50) | HRH3DRD2HRH1ACP1MEN1 | |
| SCHEMBL3389354 | 0.85 | GRIN2D (0.47) | HRH3DRD2HRH1 | |
| SCHEMBL3389303 | 0.84 | GRIN2D (0.46) | HRH3DRD2HRH1ACHE | |
| SCHEMBL3386192 | 0.84 | LMNA (0.43) | HRH3DRD2HRH1ACHEMAPT | |
| SCHEMBL3388497 | 0.83 | HRH3 (0.40) | HRH3HRH1ACHE | |
| SCHEMBL3386229 | 0.82 | HRH3 (0.41) | HRH3HRH1ACHE | |
| SCHEMBL3384766 | 0.82 | HRH3 (0.41) | HRH3HRH1ACHE | |
| SCHEMBL3389964 | 0.81 | KCNH2 (0.43) | HRH3 | |
| SCHEMBL3389754 | 0.80 | ALDH1A1 (0.44) | DRD2 | |
| SCHEMBL3921129 | 0.80 | CYP2D6 (0.46) | HRH3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | claimed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | claimed |
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024224064-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| US-20220048892-A1 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2022-02-17 | — | — | US | disclosed |
| EP-3902544-A1 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020138271-A1 | HETEROCYCLIC DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-02 | — | — | WO | disclosed |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| EP-1756104-B1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | disclosed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1756104-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | Pfizer Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111036-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LIMITED (GB) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | disclosed |
| EP-1595881-A1 | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands | Pfizer Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | HRH3 2211/4885DRD2 2628/4885HRH1 1471/4885 |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | HRH3 2/4885DRD2 169/4885HRH1 3/4885 |
| US-20220048892-A1 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | SCN8A, SCN7A, SCN1A | HRH3 2211/4885DRD2 2628/4885HRH1 1471/4885 |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | HRH4, HRH3, HRH1 | HRH3 2/4885DRD2 169/4885HRH1 3/4885 |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | HRH3 3662/4885DRD2 4777/4885HRH1 2813/4885 |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | HRH3 3662/4885DRD2 4777/4885HRH1 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.